Wednesday, June 17, 2026

Polyphenol-rich diets associated with lower long-term cardiovascular disease risk

›
People who regularly consume polyphenol-rich foods and drinks, such as tea, coffee, berries, cocoa, nuts, whole grains and olive oil, may ha...
Tuesday, June 16, 2026

Lilly's announces results from Phase III clinical trial of Jaypirca

›
In continuation of my update on  pirtobrutinib Eli Lilly and Company announced results from the Phase 3 BRUIN CLL-322 clinical trial of Jayp...

Alternative sweetener sorbitol linked to liver disease

›
Sweeteners such as aspartame, found in Equal packets, sucralose (Splenda), or sugar alcohols are often seen as healthier alternatives to foo...
Monday, June 15, 2026

Drug developed for inherited bleeding disorder shows promising trial results

›
Hereditary hemorrhagic telangiectasia (HHT) is the second most common inherited bleeding disorder worldwide, affecting one in 3,800 persons....
Saturday, June 13, 2026

Eylea HD (aflibercept) Approved by FDA for the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing Across Approved Indications

›
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced the U.S. Food and Drug Administration (FDA) approval of Eylea HD (aflibercept) Inje...
Thursday, June 11, 2026

Ofirnoflast (HT-6184) Receives Orphan Drug Designation from U.S. FDA for Myelodysplastic Syndromes

›
Halia Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering therapies that target the root causes of inflammation-driven...
Monday, June 8, 2026

Genentech’s Fenebrutinib Shows Unprecedented Positive Phase III Results as the Potential First and Only BTK Inhibitor in Both Relapsing and Primary Progressive Multiple Sclerosis

›
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the first Phase III (FENhance 2) of two pivotal, s...
Saturday, June 6, 2026

U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Iberdomide in Patients with Relapsed or Refractory Multiple Myeloma

›
Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) ...
Friday, June 5, 2026

Deciphera Pharmaceuticals Announces U.S. Food and Drug Administration Acceptance for Filing of New Drug Application for Tirabrutinib in Patients with Relapsed or Refractory PCNSL

›
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), t...
Thursday, June 4, 2026

FDA Grants Orphan Drug Designation for Tinostamustine in Malignant Glioma

›
Purdue Pharma L.P. (“Purdue”) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to ...
Wednesday, June 3, 2026

Icotrokinra Beneficial for Adults, Teens With Plaque Psoriasis

›
For adults and adolescents with moderate-to-severe  plaque psoriasis , selective blockade of the interleukin-23 receptor with the targeted o...
Tuesday, June 2, 2026

FDA Approves Clotic (clotrimazole otic solution), First Treatment with Clinical Evidence for Fungal Ear Infections

›
In continuation of my update on  clotrimazole Laboratorios Salvat, S.A. ("Salvat") announced today that the U.S. Food and Drug Adm...
Monday, June 1, 2026

Bictegravir and lenacapavir: What is it and is it FDA approved?

›
In continuation of my update on  lenacapavir   lenacapavir   Bictegravir Bictegravir plus lenacapavir (BIC/LEN) is an integrase strand trans...
Saturday, May 30, 2026

Tomato-Soy Juice Shows Promise Against Chronic Inflammation

›
A simple juice made from tomatoes and soybeans may help lower harmful inflammation linked with obesity and chronic disease , according to a...